Latest guidelines for management of hypertension in pregnancy
Reading File
Finding Sources
Searching PubMed
"hypertension" AND "pregnancy" AND "management"
Searching the Web
hypertension in pregnancy management guidelines 2024 2025 ACOG ISSHP
Reading File
Reading File
Reading Web Page
hypertension pregnancy management guidelines treatment targets antihypertensives
Searching PubMed
"hypertensive disorders of pregnancy" AND "guidelines"
Reading File
Reading Article
I now have comprehensive, high-quality information from multiple authoritative sources. Let me compile the full response.
Management of Hypertension in Pregnancy — Current Guidelines
1. Classification
Hypertensive disorders of pregnancy (HDP) affect ~10% of all pregnancies and are classified as:
| Category | Definition |
|---|---|
| Chronic/pre-existing hypertension | BP ≥140/90 mmHg before 20 weeks or pre-pregnancy |
| Gestational hypertension | New-onset BP ≥140/90 mmHg ≥20 weeks, no proteinuria/features |
| Pre-eclampsia | New-onset HTN ≥20 weeks + proteinuria (≥300 mg/24h) OR severe features (below) |
| Superimposed pre-eclampsia | Pre-eclampsia developing in a woman with chronic hypertension |
| Eclampsia | Pre-eclampsia with new-onset seizures |
Pre-eclampsia with severe features includes: thrombocytopenia (<100×10⁹/L), impaired liver function (AST/ALT >2× upper limit), new renal insufficiency, pulmonary oedema, new-onset headache unresponsive to analgesia, or visual disturbances. Proteinuria is no longer required if severe features are present (ACOG 2013, ISSHP 2018).
2. When to Start Antihypertensive Treatment
2024 ESC Guidelines (most current major guideline)
- Gestational hypertension: Start drug treatment when confirmed systolic BP ≥140 mmHg OR diastolic BP ≥90 mmHg (Class I, Level B)
- Pre-existing hypertension + subclinical organ damage OR symptoms: Start ≥140/90 mmHg (Class I, Level C)
- All other cases (isolated pre-existing HTN, low risk): Start when systolic ≥150 mmHg or diastolic ≥95 mmHg (Class I, Level C)
- Severe hypertension (>160/110 mmHg): Immediate drug treatment, Class I, Level C
ACOG (2019 reaffirmed)
- Previously recommended against treatment of mild-moderate HTN (<160/105 mmHg) in chronic hypertension without end-organ damage
- However, the CHIPS trial (Magee 2015) showed that targeting DBP 85 mmHg ("tight control") vs. DBP 100 mmHg ("less-tight") was safe — no difference in pregnancy loss or neonatal outcomes — and significantly reduced maternal severe hypertension (27.5% vs. 40.6%), thrombocytopenia, and transaminitis. This has shifted consensus toward tighter control.
SOMANZ 2023 (Australia/New Zealand)
Updated guidelines include 39 recommendations covering screening, prevention, diagnosis, and management. Key changes include first-trimester combined screening for pre-eclampsia risk and recommendations on angiogenic biomarkers (sFlt-1/PlGF ratio).
3. BP Targets During Treatment
| Setting | Target |
|---|---|
| Mild–moderate HTN | SBP 130–150 / DBP 80–95 mmHg (ESC 2024) |
| Tight control (CHIPS) | DBP 85 mmHg — now preferred over 100 mmHg |
| Avoid | SBP <130 mmHg (risk of placental underperfusion) |
4. Antihypertensive Drug Selection
Safe in Pregnancy (Oral, Chronic Management)
| Drug | Dosing | Notes |
|---|---|---|
| Methyldopa | 250 mg BD (can titrate) | Longest safety record; first-line especially in 1st trimester |
| Labetalol | 100 mg BD–800 mg/day | α+β blocker; very widely used |
| Nifedipine (modified release) | 30–60 mg OD | Preferred CCB; avoid short-acting nifedipine sublingually |
| Hydralazine | 25–50 mg BD–TID | Oral option; 2nd line |
Acute/Severe Hypertension (IV/Acute Use)
| Drug | Route | Dosing |
|---|---|---|
| Labetalol IV | IV bolus | 20 mg IV; escalate to 40–80 mg every 10 min; max 300 mg total |
| Hydralazine IV/IM | IV/IM | 5–10 mg IV; repeat every 20 min as needed |
| Nifedipine oral | Oral | 10–20 mg immediate-release; repeat in 30 min if needed |
| Nitroglycerin (GTN) IV | IV infusion | Pre-eclampsia with pulmonary oedema (ESC 2024, Class I, Level C) |
Absolutely Contraindicated in Pregnancy
- ACE inhibitors (captopril, enalapril, lisinopril) — fetotoxic, renal tubular dysgenesis
- ARBs (losartan, valsartan) — same mechanism, teratogenic
- Direct renin inhibitors (aliskiren)
- Atenolol — associated with fetal growth restriction
5. Prevention of Pre-eclampsia
- Low-dose aspirin (75–150 mg/day, ideally starting <16 weeks): Recommended for women at high risk of pre-eclampsia (prior pre-eclampsia, CKD, diabetes, hypertension, autoimmune disease, multifetal pregnancy). Reduces risk by ~10–20%.
- Calcium supplementation (1.5–2 g/day): Particularly in populations with low dietary calcium intake; reduces pre-eclampsia risk.
- Exercise: Low-to-moderate intensity aerobic exercise recommended in all pregnant women without contraindications (ESC 2024, Class I, Level B).
- sFlt-1/PlGF ratio <38: Rules out pre-eclampsia within 1 week (SOMANZ 2023 recommends in diagnostic pathway).
6. Management of Pre-eclampsia
Non-severe (expectant management)
- Hospitalization not mandatory if BP controlled and no severe features
- Monitor: BP twice daily, proteinuria, LFTs, FBC, creatinine, fetal growth, umbilical Doppler
- Consider delivery at ≥37 weeks
Severe pre-eclampsia
- Delivery is the definitive treatment
- ≥34 weeks: Deliver after stabilization
- 24–34 weeks: Balance maternal vs. fetal risk; corticosteroids for fetal lung maturity
- <24 weeks: Delivery generally recommended given poor prognosis
- Magnesium sulfate: 4–6 g IV loading dose then 1–2 g/hr infusion — indicated for:
- Eclampsia (seizure treatment AND prevention of recurrence)
- Severe pre-eclampsia with CNS features (headache, visual disturbances, altered consciousness)
- Reduces eclampsia risk by ~50%
- Control BP to <160/110 mmHg acutely
HELLP Syndrome
- Haemolysis + Elevated Liver enzymes + Low Platelets
- Delivery is the treatment, usually after maternal stabilization
- Dexamethasone may be used antepartum (>34 weeks) for fetal lung maturation
7. Postpartum Management
- BP can paradoxically rise in the first 3–5 days postpartum — monitor closely
- Magnesium sulfate: Continue for 24–48 h postpartum if started antepartum for seizure prophylaxis (~20% of eclampsia occurs >48h after delivery)
- Avoid NSAIDs postpartum in women with HTN or pre-eclampsia (can raise BP and worsen renal function)
- Safe antihypertensives for breastfeeding: nifedipine, labetalol, enalapril (one of the few ACE inhibitors considered acceptable postpartum in breastfeeding)
- Review/wean antihypertensives as BP often normalizes; BP ≥150/100 postpartum warrants treatment
- Long-term follow-up: Women with pre-eclampsia have 2× lifetime risk of cardiovascular disease, stroke, and hypertension — counsel accordingly
8. Secondary Hypertension in Pregnancy
Consider secondary causes (affecting ≥10% of chronic HTN in pregnancy) when HTN is severe/resistant:
- Renal artery stenosis (MR angiography preferred over CT)
- Phaeochromocytoma (screen with 24h urinary catecholamines/metanephrines — can be fatal if missed)
- Primary hyperaldosteronism (aldosterone:renin ratio less reliable in pregnancy)
- Obstructive sleep apnoea (40% of hypertensive pregnant women in one study)
Key Guideline Sources
- 2024 ESC Guidelines for the management of elevated blood pressure — includes dedicated section 9.2 on hypertension in pregnancy
- ACOG Task Force on Hypertension in Pregnancy (2019 update)
- ISSHP 2018 living guideline (updated classification and management)
- SOMANZ 2023 — PMID 38763516 — 39 evidence-based recommendations including first-trimester screening and angiogenic biomarker use
- CHIPS Trial (Magee, NEJM 2015) — supports DBP 85 mmHg as safe and effective target
- Brenner & Rector's The Kidney, 2-Vol Set — Comprehensive Clinical Management section
- Goodman & Gilman's Pharmacological Basis of Therapeutics — Drug safety in pregnancy
This is a shared conversation. Sign in to Orris to start your own chat.